Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: From bench to bedside

Journal of Neuro-Oncology

Volumn 65, Issue 1, 2003, Pages 37-48

  Husain, Syed R ^a   Puri, Raj K ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anti tumor activity; Brain tumor; Fusion protein; Glioblastoma; IL 13 cytotoxin clinical trial; IL 13 receptor; IL 13 PE38; Nude mice; Receptor targeting; Tumor regression

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTOKINE; INTERLEUKIN 13; INTERLEUKIN 13 CYTOTOXIN; INTERLEUKIN 13 RECEPTOR; PSEUDOMONAS EXOTOXIN; STEROID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BRAIN CELL; BRAIN EDEMA; BRAIN NECROSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MONKEY; MUTATION; NEUROTOXICITY; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PROTEIN EXPRESSION; RAT; REVIEW; SKIN TOXICITY; TOXICOLOGICAL PARAMETERS; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; EXOTOXINS; GLIOMA; HUMANS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; PSEUDOMONAS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; RECOMBINANT FUSION PROTEINS;

EID: 0344876629     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026242432647     Document Type: Review

References (65)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, Edwards BK (eds): SEERS Cancer Statistics Review, 1973-1997, National Cancer Institute. NIH Pub. No. 00-2789. Bethesda, MD, 2000
2. National Center for Health Statistics for the United States: Public Health Service, Washington DC, 1997.
3. Galanis E, Buckner JC, Dinapoli RP et al.: Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 89: 425-430, 1998
4. Brandes A, Ermani M, Basso U, Amista P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S: Ann Oncol 12: 1, 2001
5. Brandes A, Vastola F, Monfardini S: Am J Clin Oncol 22: 287, 2001
6. Grana C, Chinol M, Robertson C et al.: Br J Cancer 86: 207-212, 2002
7. Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, Marsault C, Philippon J, Klatzmann D: Long term survival after gene therapy for a recurrent glioblastoma. Neurology 58: 1109-1112, 2002
8. Lam PYD, Breakfield XO: Potential of gene therapy for brain tumors. Human Mol Genet 10: 777-787, 2001
9. Deen DF, Chiarodo A, Frimm EA, Fike JR, Israel MA, Kun LF, Levin FA, Marton LJ, Packer RJ, Pegg AE, Rosenblum ML, Suit HD, Walker MD, Wikstrand CJ, Wilson CB, Wong AJ, Yung WKA: Brain tumor working group report on the 9th international conference on brain tumor research and therapy. J Neuro-Oncol 16: 243-272, 1993
10. Hao CH, Parney IF, Roa WH et al.: Cytokine and cytokine receptor mRNA expression in human glioblastoma: Evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol 103; 171-178, 2002
11. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor antisense gene therapy. Proc Natl Acad Sci 93: 2909-2914, 1996
12. Yamada SM, Yamada SH, Takahashi H, Teramoto A, Matsumoto K: Fibroblast growth factor receptor (FGFR)4 correlated with the malignancy of human astrocytoma. Neurological Res 24: 244-248, 2002
13. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with monoclonal antibody against vascular endothelial growth factor receptor. Cancer Res 61: 6624-6628, 2001
14. Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G, Aiken RD: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I in malignant astrocytomas. J Clin Oncol 19(8): 2189-2200, 2001
15. Crombet T, Torres O, Rodriguez V et al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study. Hybridoma 20: 131-136, 2001
16. Kreitman RJ: Immunotoxin in cancer therapy. Curr Opin Immunol 11: 570-578, 1999
17. Brandes AA, Basso U, Pasetto LM, Ermani B: New strategy developments in brain tumor therapy. Curr Pharm Design 7: 1553-1580, 2001
18. Basso U, Ermani B, Vastola F, Brandes AA: Non-cytotoxic therapies for malignant glioma. J Neuro-Oncol 58: 57-69, 2002
19. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, Vitetta ES: A Phase I study of an anti-CD22-deglycosylated Ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82: 2624-2633, 1993
20. Phillips PC, Levow C, Caterall M, Colvin OM, Pastan I, Brem H: Transforming growth factor - Pseudomonas exotoxin fusion protein (TGF-Pe38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res 54: 1008-1015, 1994
21. Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA: Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst 94: 597-606, 2002
22. Li C, Hall WA, Jin N, Panoskaltsis-Mortari A, Vallera DA: Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng 15: 419-427, 2002
23. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med 3: 1362-1368, 1997
24. Oldfield EH, Youle RJ: Immunotoxin for brain tumor therapy. Curr Opin Microbiol 234; 97-114, 1998
25. Brown KD, Zurawski SM, Mosmann TR, Zurawski G: A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 142: 679, 1989
26. Minty A, Chalon P, Derocq J-M, Dumont X, Guillemot J-C, Kaghad M, Labit C, Leplatois P, Miloux B, Minty C, Casellas P, Loison G, Lupker J, Shire D, Ferrara P, Caput D: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362: 248, 1993
27. Zurawski G, DeVries JE: Interleukin-13 is an interleukin-4-like cytokine that acts on monocytes and B cells but not on T cells. Immunol Today 15: 19-26, 1994
28. Defrance T, Carayon P, Billian G, Guillemot J-C, Minty A, Caput D, Ferrara P: Interleukin-13 is a B cell stimulatory factor. J Exp Med 179, 135-143, 1994
29. Herber J-M, Savi P, Laplace MC, Lale A, Dol F, Dumas A, Labit C, Minty A: IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes. FEBS Lett 328: 268-270, 1993
30. Obiri NI, Debinski W, Leonard WJ, Puri RK: Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukin 2, 4, 7, 9, and 15. J Biol Chem 270: 8797, 1995
31. Idzerda RL, March CJ, Mosley B, Lyman SD, Bos TV, Gimpel SD, Din WS, Grabstein KH, Widmer MB, Park LS, Cosman D, Beckman MP: Human interleukin 4 receptor confers biological responses and defines a novel receptor superfamily. J Exp Med 171; 861-873, 1990
32. Puri RK, Leland P, Kreitman RJ, Pastan I: Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL-4-Pseudomonas exotoxin chimeric protein. Int J Cancer 58: 574-581, 1994
33. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK: Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1: 1253-1258, 1995
34. Husain SR, Obiri NI, Gill P, Zheng T, Pastan I, Debinski W, Puri RK: Receptors for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res 3: 151-156, 1997
35. Obiri NI, Murata T, Debinski W, Puri RK: Modulation of interleukin (IL)-13 binding and signaling by the γc chain of the IL-2 receptor. J Biol Chem 272: 20251-20258, 1997
36. Murata T, Husain SR, Mohri RK: Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol 10: 1103-1110, 1998
37. Obiri NI, Leland P, Murata T, Debinski W, Puri RK: The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor complex. J Immunol 158: 756-764, 1997
38. Miloux B, Laurent P, Bonnin O, Luker J, Caput D, Vita N, Ferrara P: Cloning of the human IL-13Ralpha1 chain and reconstitution with the IL-4Ralpha of functional IL-4/IL-13 receptor complex. FEBS Lett 401: 163-166, 1997
39. Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola NA, Wilson TA: Cloning and characterization of binding subunits of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci 93: 497-501, 1996
40. Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard W: cDNA cloning and characterization of the human interleukin 13 receptor α chain. J Biol Chem 271: 29265-29670, 1996
41. Murata T, Obiri NI, Puri RK: Structure and signal transduction through interleukin-4 and interleukin-13 receptors, Int J Mol Med 1: 551-557, 1998
42. Kawakami M, Leland P, Kawakami K, Puri RK: Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res 12: 459-467, 2001
43. Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N, Ferrara P: Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to IL-5 receptor α chain. J Biol Chem 271: 16921-16926, 1996
44. Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O'Hara Jr. RM, Beier DR, Turner KJ, Wood CR, Collins M: The murine IL-13 receptor α2: Molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol 161: 2317-2324, 1998
45. Murata T, Obiri NI, Debinski W, Puri RK: Structure of IL-13 receptor: Analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Comm 238: 90-94, 1997
46. Joshi BH, Husain SR, Puri RK: Preclinical studies with IL-13PE38QQR for therapy of malignant glioma. Drug New Perspect 13: 599-605, 2000
47. Husain SR, Puri RK: Interleukin-13 fusion cytotoxin as a potent targeted drug for AIDS-Kaposi's sarcoma xenograft. Blood 95: 3506-3513, 2000
48. Kawakami K, Kawakami M, Snoy P, Husain SR, Puri RK: In vivo overexpression of IL-13 receptor α2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 196: 1743-1754, 2001
49. Kawakami K, Husain SR, Bright RK, Puri RK: Gene transfer of interleukin 13 receptor α2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther 8: 861-868, 2001
50. Schnyder B, Lugi S, Fenf N, Etter H, Lutz RA, Ryffel B, Sugamura K, Wunderli-Allenspach H, Moser R: Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common γ chain. Blood 87: 4286-4295, 1996
51. Vita N, Lefort S, Laurent P, Caput D, Ferrara P: Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types. J Biol Chem 270: 3512-3517, 1995
52. Kawakami K, Taguchi J, Murata T, Puri RK: The interleukin-13 receptor α2 chain: An essential component for binding and internalization but not interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97: 2673-2679, 2001
53. Joshi BH, Plautz GE, Puri RK: Interleukin-13 receptor a chain: A novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60: 1168-1172, 2000
54. Debinski W, Obiri NI, Pastan I, Puri RK: A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 270: 16775-16780, 1995
55. Pastan I, Chaudhary VK, FitzGerald D: Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 61: 331-354, 1992
56. Joshi BH, Kawakami K, Leland P, Puri RK: Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: Differential sensitivity of to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 8: 1948-1956, 2002
57. Husain SR, Joshi BJ, Joshi, Puri RK: Interleukin-13 receptors as a unique target for anti-glioblastoma therapy. Int J Cancer 92: 168-175, 2001
58. Weingart J, Strauss LC, Grossman SA, Markett J, Tatter S, Fisher JD, Fleming CK, Puri RK: Phase I/II study: Intratumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Neuro-oncology 4: 379, 2002
59. Weingart J, Grossman SA, Bohan E, Fisher JD, Strauss L, Puri RK: Phase I/II study of interstitial infusion of IL13-PE38QQR cytotoxin in recurrent malignant glioma. First Quadrennial Meeting-World Federation of Neuro-Oncology. November 15-17, Washington, DC, 2001
60. Prados MD, Lang FF, Strauss L, Fleming C, Alalpe K, Kunwar S, Yung WKA, Chang S, Husain SR, Gutin P-H, Raizer J, Piepmeier JM, Berger M, McDermott M, Puri RK: Intratumoral and intracerebral microinfusion of IL13-PE38QQR cytotoxin: Phaase I/II study of pre- and post-resection infusions in recurrent resectable malignant glioma. Am Soc Clin Oncol 2002
61. Lang F, Kunwar S, Strauss L, Gutin P, Piepmeier J, McDermott M, Fleming C, Sherman J, Raizer J, Alalpe K, Yung WKA, Husain SR, Chang S, Berger M, Prados M, Puri RK: A clinical study of convection-enhanced delivery of IL13-PE38QQR cytotoxin pre- and post-resection of recurrent GBM. Am Soc Neuro-Oncol Chicago, April 2002
62. Prados MD, Lang FF, Sherman JW, Strauss LC, Fleming CK, Alalpe K, Kunwar S, Yung WKA, Chang SM, Husain SR, Gutin PH, Raizer J, Piepmeier JM, Berger M, McDermott M, Puri RK: Convection-enhanced delivery (CED) by positive pressure infusion for intra-tumoral and peri-tumoral administration of IL13-PE38QQR a recombinant tumor-targeted cytotoxin in recurrent malignant glioma. Neuro-Oncology 4: S78, 2002
63. Prados MD, Lang FF, Strauss LC, Fleming CK, Alalpe K, Kunwar S, Yung WKA, Husain SR, Chang SM, Gutin PH, Raizer J, Piepmeier JM, Berger M, Puri RK: Pre- and post-resection interstitial infusion of IL13-PE38QQR cytotoxin: Phase I study in recurrent resectable malignant glioma. World Federation of Neuro-Oncology First Quadrennial Meeting/Society for Neuro-Oncology Sixth Annual Meeting, Washington DC, Nov. 15-18, 2001
64. Kawakami K, Joshi BH, Puri RK: Sensitization of cancer cells to interleukin-13-Pseudomonas exotoxin-induced cell death by gene transfer of interleukin-13α chain. Hum Gene Ther 11: 1829-1835, 2000
65. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6: 2157-2165, 2000